4DMedical Announces Issuance of 102,537 Shares with Cleansing Notice Filed on 1 July 2026

4DMedical Issues 102,537 Fully Paid Ordinary Shares on 1 July 2026

In its company update dated 1 July 2026, 4DMedical Limited announced the issuance of 102,537 fully paid ordinary shares. On the same day, the company lodged two Appendix 2A forms with the ASX, which are standard notifications for security issuances. These shares, referred to as "New Shares," rank equally with existing shares in 4DMedical.

The announcement did not specify the issue price, recipients, or the intended use of the shares. Investors seeking additional details on the allocation or rationale behind this issuance may need to consult further disclosures or reach out directly to the company's Investor Relations team. No information regarding the total capital raised or price per share was provided in this update.

Implications of the Section 708A Cleansing Notice for Shareholders

The cleansing notice filed under section 708A(5)(e) of the Corporations Act 2001 enables the newly issued shares, which were distributed without a full disclosure document such as a prospectus, to be freely traded on the ASX. Without this notice, recipients would face restrictions on reselling these shares to retail investors. By lodging the cleansing notice, 4DMedical has met the legal requirements allowing these New Shares to enter the market without limitations.

For current shareholders, this means the 102,537 shares can now circulate in the secondary market. Although this number is relatively small compared to many capital raises on the ASX, any issuance can cause slight dilution. The extent of dilution depends on the total shares outstanding, which was not disclosed in this update. Investors may refer to 4DMedical’s latest Annual Report or Appendix 3B filings to determine the current share count.

4DMedical’s Compliance Statements Under the Corporations Act

As part of the cleansing notice requirements, 4DMedical confirmed that as of 1 July 2026, it complies with Chapter 2M of the Corporations Act, which governs financial reporting and audit obligations for disclosing entities. This confirmation is a standard but crucial component of a valid cleansing notice, underscoring the company’s commitment to transparent financial disclosure.

The company also affirmed compliance with sections 674 and 674A of the Corporations Act, which mandate immediate disclosure of material information and outline related civil penalties. Furthermore, 4DMedical stated that there is no excluded information as defined in sections 708A(7) or 708A(8), indicating no undisclosed material information that would affect investment decisions regarding the New Shares.

Two Appendix 2A Filings Submitted Alongside the Cleansing Notice

The cleansing notice references two Appendix 2A filings lodged with the ASX on 1 July 2026. Appendix 2A is the formal notification used by listed companies to report the issue of securities, detailing the number, class, and date of issue. The presence of two filings suggests the shares may have been issued in two separate tranches or under different arrangements, though the company did not provide further details.

Investors interested in the specifics of each issuance can access these documents via the ASX market announcements platform. The cleansing notice cross-references these filings to ensure a complete and consistent public record of the share issuance.

Contextflow Acquisition and Its Role in 4DMedical’s AI Expansion

While the cleansing notice is primarily procedural, it coincides with a pivotal phase in 4DMedical’s growth. The company highlights its 2026 acquisition of contextflow, a medical imaging AI firm, as a significant strategic development. This acquisition builds upon 4DMedical’s AI capabilities established since acquiring Imbio in 2023, enhancing its platform for respiratory disease diagnosis and management.

Share issuances like this one are sometimes linked to acquisition payments, employee incentives, or other corporate purposes. However, 4DMedical has not confirmed any connection between these New Shares and the contextflow acquisition or other corporate events. Investors should watch for further disclosures or investor briefings for clarification.

4DMedical’s XV Technology and SaaS Model Drive Growth Strategy

At the core of 4DMedical’s commercial offerings is its patented XV Technology®, which converts standard scans into functional insights to aid earlier and more precise lung disease detection and monitoring. Its software suite includes the FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®), CT LVAS™, and the CT:VQ™ solution, which integrates ventilation and perfusion analysis for cardiothoracic imaging.

These products are delivered through a Software-as-a-Service (SaaS) model that integrates with existing hospital infrastructure. This model offers investors potential for recurring revenue and scalability without proportional hardware costs. Key metrics such as customer acquisition, contracted revenue, and clinical adoption remain critical to assessing 4DMedical’s growth, though this update did not provide such data.

FDA Clearance of XV LVAS and Regulatory Outlook

A major milestone for 4DMedical has been FDA clearance of its XV Lung Ventilation Analysis Software, a vital step for accessing the large U.S. healthcare market. This clearance supports commercialization of XV technology in U.S. medical institutions.

The company’s pipeline, including CT LVAS™ and CT:VQ™, indicates ongoing efforts to expand cleared software offerings. Investors should monitor regulatory submissions, approvals, and clinical validations as 4DMedical continues to develop its SaaS portfolio and broaden market access.

Dual Headquarters in Melbourne and Los Angeles Reflect Global Strategy

4DMedical maintains dual headquarters: its registered office at Level 7 Melbourne Connect, 700 Swanston Street, Carlton VIC 3053, Australia, and a U.S. office at 21255 Burbank Boulevard, Suite 120, Woodland Hills, California. This structure supports a strong Australian base while pursuing commercial growth in the U.S., a key market for FDA-cleared medical imaging software.

The California location situates 4DMedical near numerous U.S. healthcare providers and medical technology firms, facilitating partnerships and market access. This global footprint presents opportunities and challenges, including currency exposure, regulatory differences, and managing a distributed workforce. Market participants will observe how the company balances these factors as it scales.

Investor Considerations Following the 1 July 2026 Share Issuance

The immediate market impact of this cleansing notice and share issuance was not evident from public information. Such notices are procedural and may not prompt significant share price movements, especially given the relatively small number of shares issued compared to the company’s total capital. However, in light of the recent contextflow acquisition and ongoing commercialization efforts, investors will be attentive to any subsequent disclosures clarifying the purpose of the New Shares.

Key upcoming milestones include details on share allocation, updates on integrating contextflow’s AI into 4DMedical’s platform, progress in U.S. adoption of XV LVAS and related products, and financial or trading updates revealing revenue growth under the SaaS model. For further information, investors can contact 4DMedical’s investor relations team at [email protected]. Media inquiries are handled by Julia Maguire at [email protected].